Comments on: Alfasigma Pays $300M for Rights to GSK Rare Liver Disease Drug On Track for FDA Decision

Comments on: Alfasigma Pays $300M for Rights to GSK Rare Liver Disease Drug On Track for FDA Decision https://medcitynews.com/2026/03/alfasigma-gsk-primary-biliary-cholangitis-pbc-rare-liver-disease-pruritus-linerixibat-ibat-inhibitor/ Healthcare technology news, life science current events Wed, 11 Mar 2026 19:30:10 +0000 hourly 1 https://wordpress.org/?v=6.8.5